PRESS RELEASE

New PyratineXR™ Offers Hope for 14 Million-Plus Rosacea Sufferers and Others with Facial Redness

Clinical Studies Show Anti-Aging Compound Can Help “Beat Red”;
67% Less Redness, 84% Smoother Skin and 41% More Moisture

Senetek, Original Developer of Kinetin, Introduces Next Generation of
Cytokinin-Based Technology for Therapeutic Skin Care

Napa, CA (July 22, 2009) – Senetek, PLC (OTCBB: SNKTY), a Life Sciences company engaged in the research, development and commercialization of technologies that target the science of healthy aging, today announced that PyratineXR, the company’s next generation of Cytokinin-based skincare technology, is now available nationwide through select dermatologists and other physicians who comprise the PyratineXR Physicians Network. The national launch comes just months after Senetek unveiled PyratineXR at the American Academy of Dermatology’s 67th Annual Meeting in March. The launch will be supported by both conventional and new line media advertising which will be appearing in select markets nationwide in August. To view copies of the ads, please visit www.senetekplc.com/ads.

Physician-strength PyratineXR is clinically proven to relieve redness (erythema), soothe irritation, increase moisture and repair damaged skin quickly and effectively. Clinical studies have demonstrated that PyratineXR significantly reduces the appearance of lesions (papules and pustules), spider veins and dark spots. In addition, PyratineXR improves skin texture in just days while improving dry, flaky skin by restoring the skin’s barrier function and increasing moisture retention.

“PyratineXR has been shown to be highly beneficial for all skin types, while being ideal for sensitive skin caused by inflammatory skin conditions such as rosacea and acne, which result in facial redness in millions of people,” said Frank J. Massino, Chairman and Chief Executive Officer of Senetek PLC. “PyratineXR is the pride of Senetek research. Current therapeutic options for those with facial redness generally have major shortcomings related to tolerability and irritation. PyratineXR offers a highly effective, well-tolerated, non-irritating long-term solution.”

A clinical study entitled “Topical PRK-124 (0.125%) Lotion for Improving the Signs and Symptoms of Rosacea,” was recently published in the Journal of Drugs in Dermatology, a prestigious peer-reviewed dermatological publication (May 2009). The 12-week, open-label study concludes that PyratineXR (0.125% furfuryl tetrahydropyranyladenine) improved skin barrier function and the appearance of erythema (redness) and lesions (pustules and papules) associated with mild-to-moderate rosacea during 12 weeks of treatment. According to study data, PyratineXR produced a progressive decrease in the symptoms associated with rosacea, with an overall clinical improvement in 80% of subjects, including reduction of redness and lesions. Transepidermal Water Loss (TEWL) measurements showed a 22% decrease, which translates to an increase in the moisture retention required for healthy skin and 41% mean improvement in skin dryness as early as week four. All subject self-assessments also showed good tolerability.

In a follow-up rosacea specific study performed at the University of California, Irvine, data demonstrated that PyratineXR (0.125% furfuryl tetrahydropyranyladenine) showed continual improvement for all of the major symptoms of rosacea – redness, lesions and spider veins – throughout the entire course of a 48-week treatment period. This suggests that PyratineXR may prove helpful in such conditions as it can be used continuously, long-term, unlike other existing treatments.

“The 12-week and 48-week studies of PyratineXR showed significant decrease in the appearance of papules and pustules associated with inflammatory skin conditions such as rosacea, as well as a significant decrease in the appearance of the redness,” said Dr. Mark S. Nestor, a Board Certified Dermatologist, dermatologic surgeon and laser surgeon practicing in Aventura, Florida. “We see improvement in the appearance of fine lines and brown spots and other aspects of sun damage and aging of the skin. PyratineXR represents an exciting advance in technology for the practicing dermatologist.”

PyratineXR offers an option for inflammatory skin conditions such as rosacea, acne, sunburn and razor burn. In fact, according to the National Rosacea Society more than 14 million Americans have rosacea, yet only a small fraction receive treatment. The chronic skin disease can affect adults and children of any skin type. While the cause is unknown and there is no cure, scientific advancements are now offering rosacea sufferers hope and a way to control the signs and symptoms of this potentially life-disruptive disorder.

PyratineXR is available as a Lotion or Créme through select physicians throughout North America. For more information or to find a PyratineXR Physicians Network doctor, call 1-888-467-9728 or visit www.pyratineXR.com. To watch a brief video news segment about PyratineXR, visit http://www.youtube.com/watch?v=i8oa3N99e_o.

Senetek will also introduce three new products for PyratineXR later this year.

About Senetek PLC:
Senetek PLC (OTCBB:SNKTY) is a Life Sciences company engaged in the research, development and commercialization of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology, most recently resulting in the development of kinetin, the active ingredient in the best-selling anti-aging product sold in the North American physician market. For more information, visit the company’s websites — www.senetekplc.com, www.pyratine6.com and www.pyratinexr.com — or call 877-SENETEK (United States and Canada) or 707-259-6278 (International Locations).

###

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2008. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.

Contact:
             Bratskeir & Company
             Tara Madden
             Rebecca Levitt
             212-679-2233
             tmadden@bratskeir.com
             rlevitt@bratskeir.com